665 related articles for article (PubMed ID: 20215541)
41. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
[TBL] [Abstract][Full Text] [Related]
42. Unclassified variants identified in BRCA1 exon 11: Consequences on splicing.
Anczuków O; Buisson M; Salles MJ; Triboulet S; Longy M; Lidereau R; Sinilnikova OM; Mazoyer S
Genes Chromosomes Cancer; 2008 May; 47(5):418-26. PubMed ID: 18273839
[TBL] [Abstract][Full Text] [Related]
43. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
[TBL] [Abstract][Full Text] [Related]
44. BCoR-L1 variation and breast cancer.
Lose F; Arnold J; Young DB; Brown CJ; Mann GJ; Pupo GM; ; Khanna KK; Chenevix-Trench G; Spurdle AB
Breast Cancer Res; 2007; 9(4):R54. PubMed ID: 17697391
[TBL] [Abstract][Full Text] [Related]
45. Contributions of ATM mutations to familial breast and ovarian cancer.
Thorstenson YR; Roxas A; Kroiss R; Jenkins MA; Yu KM; Bachrich T; Muhr D; Wayne TL; Chu G; Davis RW; Wagner TM; Oefner PJ
Cancer Res; 2003 Jun; 63(12):3325-33. PubMed ID: 12810666
[TBL] [Abstract][Full Text] [Related]
46. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
Sekine M; Nagata H; Tsuji S; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Tanaka K;
Clin Cancer Res; 2001 Oct; 7(10):3144-50. PubMed ID: 11595708
[TBL] [Abstract][Full Text] [Related]
47. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
48. The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript.
Vega A; Campos B; Bressac-De-Paillerets B; Bond PM; Janin N; Douglas FS; Domènech M; Baena M; Pericay C; Alonso C; Carracedo A; Baiget M; Diez O
Hum Mutat; 2001 Jun; 17(6):520-1. PubMed ID: 11385711
[TBL] [Abstract][Full Text] [Related]
49. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
Tsongalis GJ; Linfert DR; Johnson RC; Ackroyd R; Berman MM; Ricci A
Arch Pathol Lab Med; 1998 Jun; 122(6):548-50. PubMed ID: 9625424
[TBL] [Abstract][Full Text] [Related]
50. The spectrum and incidence of BRCA1 pathogenic mutations in Slovak breast/ovarian cancer families.
Konecny M; Vizvaryova M; Weismanova E; Ilencikova D; Mlkva I; Weismann P; Machackova G; Kausitz J
Neoplasma; 2007; 54(2):137-42. PubMed ID: 17319787
[TBL] [Abstract][Full Text] [Related]
51. Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes.
Menéndez M; Castellsagué J; Mirete M; Pros E; Feliubadaló L; Osorio A; Calaf M; Tornero E; del Valle J; Fernández-Rodríguez J; Quiles F; Salinas M; Velasco A; Teulé A; Brunet J; Blanco I; Capellá G; Lázaro C
Breast Cancer Res Treat; 2012 Apr; 132(3):979-92. PubMed ID: 21735045
[TBL] [Abstract][Full Text] [Related]
52. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
[TBL] [Abstract][Full Text] [Related]
53. BRCA2 germline mutations in Cypriot patients with familial breast/ovarian cancer.
Hadjisavvas A; Charalambous E; Adamou A; Christodoulou CG; Kyriacou K
Hum Mutat; 2003 Feb; 21(2):171. PubMed ID: 12552570
[TBL] [Abstract][Full Text] [Related]
54. Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenes.
Acedo A; Sanz DJ; Durán M; Infante M; Pérez-Cabornero L; Miner C; Velasco EA
Breast Cancer Res; 2012 May; 14(3):R87. PubMed ID: 22632462
[TBL] [Abstract][Full Text] [Related]
55. Colocalisation of predicted exonic splicing enhancers in BRCA2 with reported sequence variants.
Pettigrew CA; Wayte N; Wronski A; Lovelock PK; Spurdle AB; Brown MA
Breast Cancer Res Treat; 2008 Jul; 110(2):227-34. PubMed ID: 17899372
[TBL] [Abstract][Full Text] [Related]
56. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K
BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799
[TBL] [Abstract][Full Text] [Related]
57. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
58. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
[TBL] [Abstract][Full Text] [Related]
59. Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes.
Théry JC; Krieger S; Gaildrat P; Révillion F; Buisine MP; Killian A; Duponchel C; Rousselin A; Vaur D; Peyrat JP; Berthet P; Frébourg T; Martins A; Hardouin A; Tosi M
Eur J Hum Genet; 2011 Oct; 19(10):1052-8. PubMed ID: 21673748
[TBL] [Abstract][Full Text] [Related]
60. CHEK2 1100delC and Del5395bp mutations in BRCA-negative individuals from Serbian hereditary breast and ovarian cancer families.
Krivokuca A; Dobricic J; Brankovic-Magic M
J BUON; 2013; 18(3):594-600. PubMed ID: 24065469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
